ID   MD13L_HUMAN             Reviewed;        2210 AA.
AC   Q71F56; A1L469; Q68DN4; Q9H8C0; Q9NSY9; Q9UFD8; Q9UPX5;
DT   06-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   18-JUN-2025, entry version 166.
DE   RecName: Full=Mediator of RNA polymerase II transcription subunit 13-like;
DE   AltName: Full=Mediator complex subunit 13-like;
DE   AltName: Full=Thyroid hormone receptor-associated protein 2;
DE   AltName: Full=Thyroid hormone receptor-associated protein complex 240 kDa component-like;
GN   Name=MED13L; Synonyms=KIAA1025, PROSIT240, THRAP2, TRAP240L;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, VARIANT MRFACD GLY-251,
RP   VARIANTS HIS-1872 AND GLY-2023, AND CHROMOSOMAL TRANSLOCATION.
RX   PubMed=14638541; DOI=10.1161/01.cir.0000103684.77636.cd;
RA   Muncke N., Jung C., Ruediger H., Ulmer H., Roeth R., Hubert A.,
RA   Goldmuntz E., Driscoll D., Goodship J., Schoen K., Rappold G.;
RT   "Missense mutations and gene interruption in PROSIT240, a novel TRAP240-
RT   like gene, in patients with congenital heart defect (transposition of the
RT   great arteries).";
RL   Circulation 108:2843-2850(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=15145061; DOI=10.1016/j.gene.2004.02.044;
RA   Musante L., Bartsch O., Ropers H.-H., Kalscheuer V.M.;
RT   "cDNA cloning and characterization of the human THRAP2 gene which maps to
RT   chromosome 12q24, and its mouse ortholog Thrap2.";
RL   Gene 332:119-127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 142-2210.
RC   TISSUE=Fetal kidney;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 294-2210.
RC   TISSUE=Brain;
RX   PubMed=10470851; DOI=10.1093/dnares/6.3.197;
RA   Kikuno R., Nagase T., Ishikawa K., Hirosawa M., Miyajima N., Tanaka A.,
RA   Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIV. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:197-205(1999).
RN   [6]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1077-2210.
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE MEDIATOR
RP   COMPLEX.
RX   PubMed=15175163; DOI=10.1016/j.molcel.2004.05.006;
RA   Sato S., Tomomori-Sato C., Parmely T.J., Florens L., Zybailov B.,
RA   Swanson S.K., Banks C.A.S., Jin J., Cai Y., Washburn M.P., Conaway J.W.,
RA   Conaway R.C.;
RT   "A set of consensus mammalian mediator subunits identified by
RT   multidimensional protein identification technology.";
RL   Mol. Cell 14:685-691(2004).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE MEDIATOR
RP   COMPLEX.
RX   PubMed=15989967; DOI=10.1016/j.molcel.2005.05.015;
RA   Zhang X., Krutchinsky A., Fukuda A., Chen W., Yamamura S., Chait B.T.,
RA   Roeder R.G.;
RT   "MED1/TRAP220 exists predominantly in a TRAP/Mediator subpopulation
RT   enriched in RNA polymerase II and is required for ER-mediated
RT   transcription.";
RL   Mol. Cell 19:89-100(2005).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-817; SER-826 AND SER-2083,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-817 AND SER-2083, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-553; SER-560 AND SER-817, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-923 AND SER-2083, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   INVOLVEMENT IN MRFACD.
RX   PubMed=25167861; DOI=10.1136/jmedgenet-2014-102554;
RA   Redin C., Gerard B., Lauer J., Herenger Y., Muller J., Quartier A.,
RA   Masurel-Paulet A., Willems M., Lesca G., El-Chehadeh S., Le Gras S.,
RA   Vicaire S., Philipps M., Dumas M., Geoffroy V., Feger C., Haumesser N.,
RA   Alembik Y., Barth M., Bonneau D., Colin E., Dollfus H., Doray B.,
RA   Delrue M.A., Drouin-Garraud V., Flori E., Fradin M., Francannet C.,
RA   Goldenberg A., Lumbroso S., Mathieu-Dramard M., Martin-Coignard D.,
RA   Lacombe D., Morin G., Polge A., Sukno S., Thauvin-Robinet C., Thevenon J.,
RA   Doco-Fenzy M., Genevieve D., Sarda P., Edery P., Isidor B., Jost B.,
RA   Olivier-Faivre L., Mandel J.L., Piton A.;
RT   "Efficient strategy for the molecular diagnosis of intellectual disability
RT   using targeted high-throughput sequencing.";
RL   J. Med. Genet. 51:724-736(2014).
RN   [15]
RP   INVOLVEMENT IN MRFACD.
RX   PubMed=25356899; DOI=10.1371/journal.pgen.1004772;
RA   Hamdan F.F., Srour M., Capo-Chichi J.M., Daoud H., Nassif C., Patry L.,
RA   Massicotte C., Ambalavanan A., Spiegelman D., Diallo O., Henrion E.,
RA   Dionne-Laporte A., Fougerat A., Pshezhetsky A.V., Venkateswaran S.,
RA   Rouleau G.A., Michaud J.L.;
RT   "De novo mutations in moderate or severe intellectual disability.";
RL   PLoS Genet. 10:E1004772-E1004772(2014).
RN   [16]
RP   VARIANT MRFACD 160-SER--GLU-174 DEL.
RX   PubMed=24781760; DOI=10.1038/ejhg.2014.69;
RA   van Haelst M.M., Monroe G.R., Duran K., van Binsbergen E., Breur J.M.,
RA   Giltay J.C., van Haaften G.;
RT   "Further confirmation of the MED13L haploinsufficiency syndrome.";
RL   Eur. J. Hum. Genet. 23:135-138(2015).
RN   [17]
RP   INVOLVEMENT IN MRFACD.
RX   PubMed=25758992; DOI=10.1038/ejhg.2015.26;
RA   Adegbola A., Musante L., Callewaert B., Maciel P., Hu H., Isidor B.,
RA   Picker-Minh S., Le Caignec C., Delle Chiaie B., Vanakker O., Menten B.,
RA   Dheedene A., Bockaert N., Roelens F., Decaestecker K., Silva J., Soares G.,
RA   Lopes F., Najmabadi H., Kahrizi K., Cox G.F., Angus S.P., Staropoli J.F.,
RA   Fischer U., Suckow V., Bartsch O., Chess A., Ropers H.H., Wienker T.F.,
RA   Huebner C., Kaindl A.M., Kalscheuer V.M.;
RT   "Redefining the MED13L syndrome.";
RL   Eur. J. Hum. Genet. 23:1308-1317(2015).
RN   [18]
RP   INVOLVEMENT IN MRFACD.
RX   PubMed=25712080; DOI=10.1038/ejhg.2015.19;
RA   Cafiero C., Marangi G., Orteschi D., Ali M., Asaro A., Ponzi E.,
RA   Moncada A., Ricciardi S., Murdolo M., Mancano G., Contaldo I., Leuzzi V.,
RA   Battaglia D., Mercuri E., Slavotinek A.M., Zollino M.;
RT   "Novel de novo heterozygous loss-of-function variants in MED13L and further
RT   delineation of the MED13L haploinsufficiency syndrome.";
RL   Eur. J. Hum. Genet. 23:1499-1504(2015).
CC   -!- FUNCTION: Component of the Mediator complex, a coactivator involved in
CC       the regulated transcription of nearly all RNA polymerase II-dependent
CC       genes. Mediator functions as a bridge to convey information from gene-
CC       specific regulatory proteins to the basal RNA polymerase II
CC       transcription machinery. Mediator is recruited to promoters by direct
CC       interactions with regulatory proteins and serves as a scaffold for the
CC       assembly of a functional preinitiation complex with RNA polymerase II
CC       and the general transcription factors. This subunit may specifically
CC       regulate transcription of targets of the Wnt signaling pathway and SHH
CC       signaling pathway.
CC   -!- SUBUNIT: Component of the Mediator complex, which is composed of MED1,
CC       MED4, MED6, MED7, MED8, MED9, MED10, MED11, MED12, MED13, MED13L,
CC       MED14, MED15, MED16, MED17, MED18, MED19, MED20, MED21, MED22, MED23,
CC       MED24, MED25, MED26, MED27, MED29, MED30, MED31, CCNC, CDK8 and
CC       CDC2L6/CDK11. The MED12, MED13, CCNC and CDK8 subunits form a distinct
CC       module termed the CDK8 module. Mediator containing the CDK8 module is
CC       less active than Mediator lacking this module in supporting
CC       transcriptional activation. Individual preparations of the Mediator
CC       complex lacking one or more distinct subunits have been variously
CC       termed ARC, CRSP, DRIP, PC2, SMCC and TRAP.
CC       {ECO:0000269|PubMed:15175163, ECO:0000269|PubMed:15989967}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain (cerebellum), heart
CC       (aorta), skeletal muscle, kidney, placenta and peripheral blood
CC       leukocytes. Highly expressed in fetal brain.
CC       {ECO:0000269|PubMed:14638541, ECO:0000269|PubMed:15145061}.
CC   -!- DISEASE: Note=A chromosomal aberration involving MED13L is found in a
CC       patient with transposition of the great arteries, dextro-looped and
CC       intellectual disability. Translocation t(12;17)(q24.1;q21).
CC       {ECO:0000269|PubMed:14638541}.
CC   -!- DISEASE: Impaired intellectual development and distinctive facial
CC       features with or without cardiac defects (MRFACD) [MIM:616789]: An
CC       autosomal dominant syndrome characterized by intellectual disability,
CC       delayed psychomotor development, profound language impairment, and
CC       facial dysmorphism, including frontal bossing, upslanting palpebral
CC       fissures, depressed nasal bridge with bulbous tip, and macrostomia.
CC       There is variable penetrance of cardiac malformations, ranging from no
CC       malformations to patent foramen ovale to septal defects and/or
CC       transposition of the great arteries. {ECO:0000269|PubMed:14638541,
CC       ECO:0000269|PubMed:24781760, ECO:0000269|PubMed:25167861,
CC       ECO:0000269|PubMed:25356899, ECO:0000269|PubMed:25712080,
CC       ECO:0000269|PubMed:25758992}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the Mediator complex subunit 13 family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB14697.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF515599; AAQ08182.1; -; mRNA.
DR   EMBL; AY338463; AAR08418.1; -; mRNA.
DR   EMBL; BC130422; AAI30423.1; -; mRNA.
DR   EMBL; AL133033; CAB61363.1; -; mRNA.
DR   EMBL; AL137644; CAB70855.1; -; mRNA.
DR   EMBL; CR749332; CAH18186.1; -; mRNA.
DR   EMBL; AB028948; BAA82977.2; -; mRNA.
DR   EMBL; AK023837; BAB14697.1; ALT_INIT; mRNA.
DR   CCDS; CCDS9177.1; -.
DR   PIR; T42707; T42707.
DR   RefSeq; NP_056150.1; NM_015335.5.
DR   AlphaFoldDB; Q71F56; -.
DR   SMR; Q71F56; -.
DR   BioGRID; 116964; 76.
DR   CORUM; Q71F56; -.
DR   FunCoup; Q71F56; 2294.
DR   IntAct; Q71F56; 77.
DR   MINT; Q71F56; -.
DR   STRING; 9606.ENSP00000281928; -.
DR   GlyGen; Q71F56; 3 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; Q71F56; -.
DR   PhosphoSitePlus; Q71F56; -.
DR   BioMuta; MED13L; -.
DR   DMDM; 74749769; -.
DR   jPOST; Q71F56; -.
DR   MassIVE; Q71F56; -.
DR   PaxDb; 9606-ENSP00000281928; -.
DR   PeptideAtlas; Q71F56; -.
DR   ProteomicsDB; 68600; -.
DR   Pumba; Q71F56; -.
DR   Antibodypedia; 31301; 93 antibodies from 24 providers.
DR   DNASU; 23389; -.
DR   Ensembl; ENST00000281928.9; ENSP00000281928.3; ENSG00000123066.9.
DR   GeneID; 23389; -.
DR   KEGG; hsa:23389; -.
DR   MANE-Select; ENST00000281928.9; ENSP00000281928.3; NM_015335.5; NP_056150.1.
DR   UCSC; uc001tvw.4; human.
DR   AGR; HGNC:22962; -.
DR   CTD; 23389; -.
DR   DisGeNET; 23389; -.
DR   GeneCards; MED13L; -.
DR   HGNC; HGNC:22962; MED13L.
DR   HPA; ENSG00000123066; Low tissue specificity.
DR   MalaCards; MED13L; -.
DR   MIM; 608771; gene.
DR   MIM; 616789; phenotype.
DR   OpenTargets; ENSG00000123066; -.
DR   Orphanet; 369891; Developmental delay-facial dysmorphism syndrome due to MED13L deficiency.
DR   Orphanet; 216718; Isolated congenitally uncorrected transposition of the great arteries.
DR   VEuPathDB; HostDB:ENSG00000123066; -.
DR   eggNOG; KOG3600; Eukaryota.
DR   GeneTree; ENSGT00390000013680; -.
DR   HOGENOM; CLU_000508_0_0_1; -.
DR   InParanoid; Q71F56; -.
DR   OrthoDB; 103819at2759; -.
DR   PAN-GO; Q71F56; 3 GO annotations based on evolutionary models.
DR   PhylomeDB; Q71F56; -.
DR   PathwayCommons; Q71F56; -.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-9833110; RSV-host interactions.
DR   SignaLink; Q71F56; -.
DR   SIGNOR; Q71F56; -.
DR   BioGRID-ORCS; 23389; 66 hits in 1170 CRISPR screens.
DR   ChiTaRS; MED13L; human.
DR   GenomeRNAi; 23389; -.
DR   Pharos; Q71F56; Tbio.
DR   PRO; PR:Q71F56; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q71F56; protein.
DR   Bgee; ENSG00000123066; Expressed in calcaneal tendon and 212 other cell types or tissues.
DR   ExpressionAtlas; Q71F56; baseline and differential.
DR   GO; GO:0016592; C:mediator complex; IEA:InterPro.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:GO_Central.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:GO_Central.
DR   InterPro; IPR009401; Med13_C.
DR   InterPro; IPR051139; Mediator_complx_sub13.
DR   InterPro; IPR021643; Mediator_Med13_N.
DR   InterPro; IPR041285; MID_MedPIWI.
DR   PANTHER; PTHR48249; MEDIATOR OF RNA POLYMERASE II TRANSCRIPTION SUBUNIT 13; 1.
DR   PANTHER; PTHR48249:SF1; MEDIATOR OF RNA POLYMERASE II TRANSCRIPTION SUBUNIT 13-LIKE; 1.
DR   Pfam; PF06333; Med13_C; 1.
DR   Pfam; PF11597; Med13_N; 1.
DR   Pfam; PF18296; MID_MedPIWI; 1.
DR   neXtProt; NX_Q71F56; -.
DR   PharmGKB; PA162395233; -.
DR   TreeFam; TF316867; -.
PE   1: Evidence at protein level;
KW   Activator; Chromosomal rearrangement; Disease variant;
KW   Intellectual disability; Nucleus; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Repeat; Repressor;
KW   Transcription; Transcription regulation.
FT   CHAIN           1..2210
FT                   /note="Mediator of RNA polymerase II transcription subunit
FT                   13-like"
FT                   /id="PRO_0000076352"
FT   REGION          391..414
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          435..489
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          519..582
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          736..770
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1016..1096
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1380..1401
FT                   /note="Leucine-zipper"
FT   REGION          1530..1656
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2045..2080
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           669..673
FT                   /note="LXXLL motif 1"
FT   MOTIF           1225..1229
FT                   /note="LXXLL motif 2"
FT   COMPBIAS        391..400
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        445..458
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        468..480
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        533..544
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        551..560
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        736..752
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1025..1036
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1077..1092
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1531..1608
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1615..1629
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1637..1650
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         553
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         560
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         817
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332"
FT   MOD_RES         826
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         923
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2083
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   VARIANT         160..174
FT                   /note="Missing (in MRFACD)"
FT                   /evidence="ECO:0000269|PubMed:24781760"
FT                   /id="VAR_076332"
FT   VARIANT         251
FT                   /note="E -> G (in MRFACD; uncertain significance;
FT                   dbSNP:rs28940309)"
FT                   /evidence="ECO:0000269|PubMed:14638541"
FT                   /id="VAR_024024"
FT   VARIANT         1872
FT                   /note="R -> H (in a patient with dextro-looped
FT                   transposition of the great arteries; uncertain
FT                   significance; dbSNP:rs28940310)"
FT                   /evidence="ECO:0000269|PubMed:14638541"
FT                   /id="VAR_024025"
FT   VARIANT         2023
FT                   /note="D -> G (in a patient with dextro-looped
FT                   transposition of the great arteries; uncertain
FT                   significance; dbSNP:rs121918333)"
FT                   /evidence="ECO:0000269|PubMed:14638541"
FT                   /id="VAR_024026"
FT   CONFLICT        295..299
FT                   /note="PQSVA -> SISLI (in Ref. 5; BAA82977)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        861
FT                   /note="L -> S (in Ref. 4; CAH18186)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1258
FT                   /note="S -> G (in Ref. 4; CAH18186)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1455
FT                   /note="P -> L (in Ref. 7; BAB14697)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1577
FT                   /note="S -> N (in Ref. 7; BAB14697)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1703
FT                   /note="L -> M (in Ref. 7; BAB14697)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1971
FT                   /note="V -> F (in Ref. 7; BAB14697)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2194
FT                   /note="V -> A (in Ref. 7; BAB14697)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   2210 AA;  242602 MW;  A8B566B1662B570C CRC64;
     MTAAANWVAN GASLEDCHSN LFSLAELTGI KWRRYNFGGH GDCGPIISAP AQDDPILLSF
     IRCLQANLLC VWRRDVKPDC KELWIFWWGD EPNLVGVIHH ELQVVEEGLW ENGLSYECRT
     LLFKAIHNLL ERCLMDKNFV RIGKWFVRPY EKDEKPVNKS EHLSCAFTFF LHGESNVCTS
     VEIAQHQPIY LINEEHIHMA QSSPAPFQVL VSPYGLNGTL TGQAYKMSDP ATRKLIEEWQ
     YFYPMVLKKK EESKEEDELG YDDDFPVAVE VIVGGVRMVY PSAFVLISQN DIPVPQSVAS
     AGGHIAVGQQ GLGSVKDPSN CGMPLTPPTS PEQAILGESG GMQSAASHLV SQDGGMITMH
     SPKRSGKIPP KLHNHMVHRV WKECILNRTQ SKRSQMSTPT LEEEPASNPA TWDFVDPTQR
     VSCSCSRHKL LKRCAVGPNR PPTVSQPGFS AGPSSSSSLP PPASSKHKTA ERQEKGDKLQ
     KRPLIPFHHR PSVAEELCME QDTPGQKLGL AGIDSSLEVS SSRKYDKQMA VPSRNTSKQM
     NLNPMDSPHS PISPLPPTLS PQPRGQETES LDPPSVPVNP ALYGNGLELQ QLSTLDDRTV
     LVGQRLPLMA EVSETALYCG IRPSNPESSE KWWHSYRLPP SDDAEFRPPE LQGERCDAKM
     EVNSESTALQ RLLAQPNKRF KIWQDKQPQL QPLHFLDPLP LSQQPGDSLG EVNDPYTFED
     GDIKYIFTAN KKCKQGTEKD SLKKNKSEDG FGTKDVTTPG HSTPVPDGKN AMSIFSSATK
     TDVRQDNAAG RAGSSSLTQV TDLAPSLHDL DNIFDNSDDD ELGAVSPALR SSKMPAVGTE
     DRPLGKDGRA AVPYPPTVAD LQRMFPTPPS LEQHPAFSPV MNYKDGISSE TVTALGMMES
     PMVSMVSTQL TEFKMEVEDG LGSPKPEEIK DFSYVHKVPS FQPFVGSSMF APLKMLPSHC
     LLPLKIPDAC LFRPSWAIPP KIEQLPMPPA ATFIRDGYNN VPSVGSLADP DYLNTPQMNT
     PVTLNSAAPA SNSGAGVLPS PATPRFSVPT PRTPRTPRTP RGGGTASGQG SVKYDSTDQG
     SPASTPSTTR PLNSVEPATM QPIPEAHSLY VTLILSDSVM NIFKDRNFDS CCICACNMNI
     KGADVGLYIP DSSNEDQYRC TCGFSAIMNR KLGYNSGLFL EDELDIFGKN SDIGQAAERR
     LMMCQSTFLP QVEGTKKPQE PPISLLLLLQ NQHTQPFASL NFLDYISSNN RQTLPCVSWS
     YDRVQADNND YWTECFNALE QGRQYVDNPT GGKVDEALVR SATVHSWPHS NVLDISMLSS
     QDVVRMLLSL QPFLQDAIQK KRTGRTWENI QHVQGPLTWQ QFHKMAGRGT YGSEESPEPL
     PIPTLLVGYD KDFLTISPFS LPFWERLLLD PYGGHRDVAY IVVCPENEAL LEGAKTFFRD
     LSAVYEMCRL GQHKPICKVL RDGIMRVGKT VAQKLTDELV SEWFNQPWSG EENDNHSRLK
     LYAQVCRHHL APYLATLQLD SSLLIPPKYQ TPPAAAQGQA TPGNAGPLAP NGSAAPPAGS
     AFNPTSNSSS TNPAASSSAS GSSVPPVSSS ASAPGISQIS TTSSSGFSGS VGGQNPSTGG
     ISADRTQGNI GCGGDTDPGQ SSSQPSQDGQ ESVTERERIG IPTEPDSADS HAHPPAVVIY
     MVDPFTYAAE EDSTSGNFWL LSLMRCYTEM LDNLPEHMRN SFILQIVPCQ YMLQTMKDEQ
     VFYIQYLKSM AFSVYCQCRR PLPTQIHIKS LTGFGPAASI EMTLKNPERP SPIQLYSPPF
     ILAPIKDKQT ELGETFGEAS QKYNVLFVGY CLSHDQRWLL ASCTDLHGEL LETCVVNIAL
     PNRSRRSKVS ARKIGLQKLW EWCIGIVQMT SLPWRVVIGR LGRLGHGELK DWSILLGECS
     LQTISKKLKD VCRMCGISAA DSPSILSACL VAMEPQGSFV VMPDAVTMGS VFGRSTALNM
     QSSQLNTPQD ASCTHILVFP TSSTIQVAPA NYPNEDGFSP NNDDMFVDLP FPDDMDNDIG
     ILMTGNLHSS PNSSPVPSPG SPSGIGVGSH FQHSRSQGER LLSREAPEEL KQQPLALGYF
     VSTAKAENLP QWFWSSCPQA QNQCPLFLKA SLHHHISVAQ TDELLPARNS QRVPHPLDSK
     TTSDVLRFVL EQYNALSWLT CNPATQDRTS CLPVHFVVLT QLYNAIMNIL
//
